Given the rapid pace of development and availability of new oral antineoplastic agents, the purpose of this review is to provide clinicians with an up-to-date practical approach to monitoring and management of cardiovascular toxicities with the aim of improving overall outcomes for patients with cancer.

Editors

Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Authors
Rupal O’Quinn, MD

Michael G. Fradley, MD

Atul R. Chugh, MD 

Vijay U. Rao, MD, PHD

Important Dates

Date of Release: May 24, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: May 23, 2022